{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:56:04Z","timestamp":1790873764536,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2017YFC0907601"],"award-info":[{"award-number":["2017YFC0907601"]}]},{"name":"Medicine and Health Technology Innovation Project, Chinese Academy of Medical Sciences","award":["2019-I2M-2-008"],"award-info":[{"award-number":["2019-I2M-2-008"]}]},{"name":"ZHEJIANG HISUN PHARMACEUTICAL CO., LTD."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40259-020-00408-z","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:15:00Z","timestamp":1582179300000},"page":"381-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial"],"prefix":"10.1007","volume":"34","clinical-trial-number":[{"clinical-trial-number":"chictr1900022520","registry":"10.18810\/chictr"}],"author":[{"given":"Jinmei","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cibo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anbin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"issue":"9570","key":"408_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(07)60635-7.","journal-title":"Lancet."},{"issue":"10089","key":"408_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4.","journal-title":"Lancet."},{"issue":"26","key":"408_CR3","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563\u201374. https:\/\/doi.org\/10.1056\/NEJMra1406182.","journal-title":"N Engl J Med."},{"issue":"6","key":"408_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904. https:\/\/doi.org\/10.1136\/ard.2011.151027.","journal-title":"Ann Rheum Dis."},{"key":"408_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/OARRR.S44550","volume":"6","author":"A Mounach","year":"2014","unstructured":"Mounach A, El Maghraoui A. Efficacy and safety of adalimumab in ankylosing spondylitis. Open Access Rheumatol. 2014;6:83\u201390. https:\/\/doi.org\/10.2147\/OARRR.S44550.","journal-title":"Open Access Rheumatol."},{"issue":"2","key":"408_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.21563","volume":"54","author":"H Haibel","year":"2006","unstructured":"Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum. 2006;54(2):678\u201381. https:\/\/doi.org\/10.1002\/art.21563.","journal-title":"Arthritis Rheum."},{"issue":"3","key":"408_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"F Huang","year":"2014","unstructured":"Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, et al. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis. 2014;73(3):587\u201394. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202533.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"408_CR8","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1002\/art.23044","volume":"56","author":"RG Lambert","year":"2007","unstructured":"Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007;56(12):4005\u201314. https:\/\/doi.org\/10.1002\/art.23044.","journal-title":"Arthritis Rheum."},{"issue":"7","key":"408_CR9","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136\u201346. https:\/\/doi.org\/10.1002\/art.21913.","journal-title":"Arthritis Rheum."},{"issue":"6","key":"408_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2\u00a0years: long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68(6):922\u20139. https:\/\/doi.org\/10.1136\/ard.2007.087270.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"408_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/14712598.2018.1430760","volume":"18","author":"E Pelechas","year":"2018","unstructured":"Pelechas E, Voulgari PV, Drosos AA. ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2018;18(3):317\u201322. https:\/\/doi.org\/10.1080\/14712598.2018.1430760.","journal-title":"Expert Opin Biol Ther."},{"issue":"4","key":"408_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Van Der Linden","year":"1984","unstructured":"Van Der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum."},{"issue":"Suppl 2","key":"408_CR13","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1\u201344. https:\/\/doi.org\/10.1136\/ard.2008.104018.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"408_CR14","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210459.","journal-title":"Ann Rheum Dis."},{"key":"408_CR15","unstructured":"Center for Drug Evaluation NMPAN. Key considerations in clinical trial design of a biosimilar drug for adalimumab solution for injection. 2018. http:\/\/www.cde.org.cn\/dzkw.do?method=largePage&id=314814"},{"issue":"6","key":"408_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14712598.2018.1468884","volume":"18","author":"A Jones","year":"2018","unstructured":"Jones A, Ciurtin C, Ismajli M, Leandro M, Sengupta R, Machado PM. Biologics for treating axial spondyloarthritis. Expert Opin Biol Ther. 2018;18(6):641\u201352. https:\/\/doi.org\/10.1080\/14712598.2018.1468884.","journal-title":"Expert Opin Biol Ther."},{"issue":"12","key":"408_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrrheum.2015.110","volume":"11","author":"T Dorner","year":"2015","unstructured":"Dorner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11(12):713\u201324. https:\/\/doi.org\/10.1038\/nrrheum.2015.110.","journal-title":"Nat Rev Rheumatol."},{"issue":"21","key":"408_CR18","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMhle1800125","volume":"378","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med. 2018;378(21):2036\u201344. https:\/\/doi.org\/10.1056\/NEJMhle1800125.","journal-title":"N Engl J Med."},{"issue":"4","key":"408_CR19","first-page":"3","volume":"7","author":"AW Mulcahy","year":"2018","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.","journal-title":"Rand Health Q."},{"issue":"10086","key":"408_CR20","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/s0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(17)30068-5.","journal-title":"Lancet."},{"issue":"2","key":"408_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","volume":"76","author":"W Park","year":"2017","unstructured":"Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Urena S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346\u201354. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208783.","journal-title":"Ann Rheum Dis."},{"key":"408_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070956","author":"E Kaltsonoudis","year":"2019","unstructured":"Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: an 18-month comparative open-label study. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8070956.","journal-title":"J Clin Med."},{"issue":"1","key":"408_CR23","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2665-9913(19)30013-X","volume":"1","author":"H Xu","year":"2019","unstructured":"Xu H, Li Z, Wu J, Xing Q, Shi G, Li J, et al. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. Lancet Rheumatol. 2019;1(1):e35\u201343. https:\/\/doi.org\/10.1016\/S2665-9913(19)30013-X.","journal-title":"Lancet Rheumatol."},{"issue":"2","key":"408_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, Dorner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211937.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"408_CR25","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203091.","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"408_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","volume":"14","author":"E Kravvariti","year":"2018","unstructured":"Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol. 2018;14(12):727\u201340. https:\/\/doi.org\/10.1038\/s41584-018-0110-9.","journal-title":"Nat Rev Rheumatol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-020-00408-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:34:22Z","timestamp":1628616862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-020-00408-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00408-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"20 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by the Chinese National Key Technology R&D Program, Ministry of Science and Technology (Grant number: 2017YFC0907601); Medicine and Health Technology Innovation Project, Chinese Academy of Medical Sciences (Grant number: 2019-I2M-2-008) and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. Open access publication of this article was funded by Haisun BioRay Bio-pharmaceutical., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the Peking Union Medical College Hospital and Chinese Academy of Medical Sciences (no. 001402) and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed written consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"ML and XZ contributed to the study conception and design. Material preparation, data collection and analysis were performed by all authors. The first draft of the manuscript was written by JS and LH; all authors commented on subsequent versions of the manuscript. All authors read and approved the final manuscript submitted to the journal.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The datasets generated during and\/or analyzed in the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}